Skip to content

Study on the Efficacy of Dexmedetomidine Combined with Esketamine in Treating Patients with Chronic Insomnia and Depression

Study on the Effectiveness of Dexmedetomidine Combined with Esketamine in the Treatment of Chronic Insomnia with Depression

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600116763
Enrollment
Unknown
Registered
2026-01-14
Start date
2026-01-15
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic insomnia with depression

Interventions

Group A:Standard treatment
Group B:Dexmedetomidine combined with esketamine treatment

Sponsors

The People's Hospital of Shihotze City, Xinjiang
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Patients with depression aged 18-65 years, regardless of gender, ASA class I-II, meeting the diagnostic criteria for chronic insomnia as outlined in the Chinese Guideline for the Diagnosis and Treatment of Insomnia in Adults (2017 edition). 2. Prior to hospitalization, all patients received conventional treatment according to the Chinese Guideline for the Diagnosis and Treatment of Insomnia in Adults (2017 edition). The treatment involved more than two types of medications, lasted for over 3 months, and yielded poor or ineffective results. The Pittsburgh Sleep Quality Index (PSQI) score before hospitalization was >9, leading to a diagnosis of chronic primary insomnia. 3.All patients met the diagnostic criteria for depression as per the International Classification of Diseases, 11th Revision (ICD-11). The Hamilton Depression Scale (HAMD) score was >8, and the Self-Rating Depression Scale score was >52.

Exclusion criteria

Exclusion criteria: 1. Patients with sleep apnoea syndrome; 2. Patients with a history of epilepsy; 3. Patients with known alcohol abuse or drug dependency; 4. Pregnant or breastfeeding patients; 5. Patients with a history of severe head trauma; 6. Patients anticipated to present with difficult airways or severe respiratory insufficiency; 7. Patients with a history of allergy to dexmedetomidine or esketamine; 8. Patients unable to comprehend the content of relevant assessment scales.

Design outcomes

Primary

MeasureTime frame
Pittsburgh Sleep Quality Index;Hamilton Depression Scale;

Secondary

MeasureTime frame
Self-Rating Depression Scale;Somatization Symptom Self-rating Scale;Epworth Sleepiness Scale;Self-Rating Anxiety Scale;

Countries

China

Contacts

Public ContactChen Dan

The People's Hospital of Shihotze City, Xinjiang

13579741018@163.com+86 135 7974 1018

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026